Article

FDA Drug Safety Communication: FDA Asks Manufacturer of the Leukemia Drug Iclusig (ponatinib) to Suspend Marketing and Sales

The U.S. Food and Drug Administration (FDA) has asked the manufacturer of the leukemia chemotherapy drug Iclusig (ponatinib) to suspend marketing and sales of Iclusig because of the risk of life-threatening blood clots and severe narrowing of blood vessels.

The U.S. Food and Drug Administration (FDA) has asked the manufacturer of the leukemia chemotherapy drug Iclusig (ponatinib) to suspend marketing and sales of Iclusig because of the risk of life-threatening blood clots and severe narrowing of blood vessels. We will continue to evaluate the drug to further understand its risks and potential patient populations in which the benefits of the drug may outweigh the risks. Patients currently receiving Iclusig should discuss with their health care professionals the risks and benefits of continuing treatment with the drug.

Read the full statement: http://1.usa.gov/1cpugt7

Source: www.fda.gov

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Sundar Jagannath
Hadar Avihai Lev-Tov, MD
4 experts in this video
4 experts in this video
Ayodeji Adegunsoye, MD, PhD, MSc
David J. Maron, MD, FASPC, Stanford University School of Medicine
Hadar Avihai Lev-Tov, MD
Senator Vincent Polistina (R, New Jersey)
Karen Vo talks about antibullying campaigns and pediatric patients with derm conditions
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo